Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)] (ab157469)


  • Product name
    Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)]
    See all TPA Tissue Plasminogen Activator primary antibodies
  • Description
    Rabbit monoclonal [EPR7232(2)] to TPA Tissue Plasminogen Activator
  • Host species
  • Tested applications
    Suitable for: WB, IHC-Pmore details
    Unsuitable for: ICC or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to residues in Human TPA Tissue Plasminogen Activator (UniProt P00750).

  • Positive control
    • Human plasma lysate; Human cervical carcinoma tissue; Human liver tissue.
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab157469 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 63 kDa.
IHC-P 1/100 - 1/500.
  • Application notes
    Is unsuitable for ICC or IP.
  • Target

    • Function
      Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
    • Tissue specificity
      Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
    • Involvement in disease
      Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
    • Sequence similarities
      Belongs to the peptidase S1 family.
      Contains 1 EGF-like domain.
      Contains 1 fibronectin type-I domain.
      Contains 2 kringle domains.
      Contains 1 peptidase S1 domain.
    • Domain
      Both FN1 and one of the kringle domains are required for binding to fibrin.
      Both FN1 and EGF-like domains are important for binding to LRP1.
      The FN1 domain mediates binding to annexin A2.
      The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
    • Post-translational
      The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
      Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
      N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
      Characterization of O-linked glycan was studied in Bowes melanoma cell line.
    • Cellular localization
      Secreted > extracellular space.
    • Information by UniProt
    • Database links
    • Alternative names
      • Alteplase antibody
      • DKFZp686I03148 antibody
      • Plasminogen activator tissue antibody
      • Plasminogen activator tissue type antibody
      • PLAT antibody
      • Reteplase antibody
      • t PA antibody
      • T Plasminogen Activator antibody
      • t-PA antibody
      • T-plasminogen activator antibody
      • Tissue plasminogen activator (t PA) antibody
      • Tissue type plasminogen activator antibody
      • Tissue-type plasminogen activator chain B antibody
      • tPA antibody
      • TPA_HUMAN antibody
      • TPA1 antibody
      see all


    • ab157469 showing +ve staining in Human normal liver.
    • ab157469 showing +ve staining in Human normal kidney.
    • ab157469 showing +ve staining in Human normal brain.
    • ab157469 showing +ve staining in Human skeletal muscle.
    • Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)] (ab157469) at 1/1000 dilution + Human plasma lysate at 10 µg

      HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 63 kDa

    • Immunohistochemical analysis of paraffin-embedded Human cervial carcinoma tissue labeling TPA Tissue Plasminogen Activator with ab157469 1/100 dilution.
    • Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling TPA Tissue Plasminogen Activator with ab157469 at 1/100 dilution.


    This product has been referenced in:
    • Li YB  et al. miR-199a-3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2. Mol Med Rep 16:2417-2424 (2017). Read more (PubMed: 28677735) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab157469.
    Please use the links above to contact us or submit feedback about this product.


    Sign up